The Fund Grade · free · no account needed
What grade does PZFVX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
John Hancock Classic Value Fund
#209 of 500 graded active funds · value · mid segment peer group
The point · specialist footprint
PZFVX puts less of its book behind proven specialists than 77% of graded funds.
Bottom 20%
● Bottom 40%
Middle
Top 40%
Top 20%
That has mattered: over the past 2.7 years, funds with this little specialist backing trailed top-rung funds by about 3.8% per quarter and beat the S&P in only 22% of fund-quarters. If it also charges an active fee, the higher-graded alternatives deserve a look.
10,000+ funds tracked · the graded specialists among them drive every read
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
PZFVX vs the Honor Roll · share card ↗Conviction exposure
7%
of the book in specialist-converged names
Late-stage weight
16.9%
of the book in Crowded or Fading names
Active share
97.8%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
John Hancock Classic Value earns a B grade, ranking 209 of 500, with specialists holding only 7% of the fund, a relatively thin base of conviction. The early bright spots are BAX, Citigroup, and MET, where proven specialists are still building. The concern is that CVS, FMS, LEA, and TSN together represent over 15% of assets and specialists are actively leaving all four.
→ Watch CVS, FMS, LEA, and TSN closely, as specialist exits across all four at once is a meaningful concentration of fading risk.
→ The Early Conviction weight in BAX, Citigroup, and MET is the clearest case for staying, so track whether specialists continue adding to those three.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.